RFA-RM-22-004: Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 18, 2022.
From the official notice on Grants.gov, last changed October 28, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$711,824
- Typical project length3.5 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-RM-22-004 were run by National Cancer Institute (NCI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-RM-22-004 in the NIH Guide.
Key dates
| Posted | October 28, 2021 |
|---|---|
| Deadline | January 18, 2022 |
| Archived by Grants.gov | February 23, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Specifically, this FOA will be for novel and varied technology development projects to characterize rare cells at single cell level. As such, the review of the FOAs falls outside the mission and scope of any of the existing standing CSR study sections and will require additional expertise and review criteria.
Funded under RFA-RM-22-004 so far
NIH funded 6 projects under RFA-RM-22-004 in fiscal 2022 to 2025, at 3 institutions. The median yearly award was $711,824.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Three-dimensional maps of senescence in the human pancreas | Johns Hopkins University | 2025 | $874,056 |
| Single-cell label-free identification of senescence by Raman microscopy and spatial genomics | Massachusetts Institute of Technology | 2025 | $881,237 |
| Senescence-on-a-chip: Building a microphysiological 3D skin model | Columbia University Health Sciences | 2025 | $904,750 |
| Three-dimensional maps of senescence in the human pancreas | Johns Hopkins University | 2023 | $550,000 |
| Senescence-on-a-chip: Building a microphysiological 3D skin model | Columbia University Health Sciences | 2023 | $549,999 |
| Single-cell label-free identification of senescence by Raman microscopy and spatial genomics | Massachusetts Institute of Technology | 2023 | $550,000 |
Who has won Trans-NIH Research Support grants before
From fiscal 2021 to 2025, Trans-NIH Research Support (93.310) awarded $5.9 billion across 4,433 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Duke University | North Carolina | 66 | $219 million |
| The Leland Stanford Junior University | California | 104 | $176 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 82 | $154 million |
| The Johns Hopkins University | Maryland | 95 | $152 million |
| Yale Univ | Connecticut | 85 | $149 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-RM-22-004 still open?
No. It closed on January 18, 2022.
Who can apply for Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed)?
Closed January 18, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-RM-22-004?
NIH RePORTER lists 6 projects funded under RFA-RM-22-004 in fiscal 2022 to 2025, at 3 institutions. The most were at Johns Hopkins University, Massachusetts Institute of Technology, Columbia University Health Sciences.
Who has won Trans-NIH Research Support grants before?
The largest recipients over five fiscal years were Duke University, The Leland Stanford Junior University, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 4,433 awards worth $5.9 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)